Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Chagpar on the Need for Repeat Biopsy in Breast Cancer

March 12th 2013

Anees Chagpar, MD, MSc, MA, MPH, Associate Professor of Surgery (Oncology), Director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, discusses the need for repeat biopsy in patients with breast cancer.

Donna Shalala on New Healthcare Reform

March 9th 2013

Donna Shalala, PhD, President, University of Miami, discusses the new healthcare reform in the U.S.

It's All About Coverage

March 9th 2013

Physicians wondering how the Affordable Care Act (ACA) will impact their practices heard a robust defense of the new law from Donna E. Shalala, PhD, on Saturday.

Dr. Piccart on the Implications of the HERA Trial

March 9th 2013

Martine Piccart, MD, PhD, discusses the implications of the HERA trial, which looked at two years compared with one year of trastuzumab after adjuvant chemotherapy in women with HER2-positive breast cancer.

Oncology Enters Era of Genomics: Sledge Calls for Overhaul of Clinical Trials System

March 9th 2013

As the genomic era in oncology unfolds, the development of new therapeutics increasingly will involve targeting a range of mutations simultaneously, requiring a "next-generation clinical trials system" to match the advances that technology is delivering.

Piccart Discusses Translating Genomic Testing Into Practice

March 8th 2013

Two large clinical trials are expected to define the impact that employing genomic tests in treatment decisions has on survival outcomes, according to Martine J. Piccart, MD, PhD.

Grappling With Healthcare Upheaval

March 8th 2013

Oncology leaders are bracing for a host of changes in the healthcare system, not only as a result of the recently upheld insurance reform legislation but also because of continued pressure to control the ever-rising cost of cancer care.

Dr. Lisa A. Carey Discusses Psycho-Oncology

March 8th 2013

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the field of psycho-oncology.

Dr. Ron Bose on HER2 Gene Mutations in Breast Cancer

March 8th 2013

Ron Bose, MD, PhD, from the Siteman Cancer Center, discusses the prevalence of HER2 gene mutations in patients diagnosed with breast cancer.

Coping With Burnout? Tips on Handling This Occupational Hazard

March 8th 2013

Burnout is described as a syndrome of "emotional exhaustion, depersonalization, and feelings of low personal accomplishment," and is an increasingly problematic condition among physicians for a multitude of reasons.

Dr. Rugo on the Standard for Front-Line Chemotherapy

March 8th 2013

Hope S. Rugo, MD, at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the standard for front-line chemotherapy in patients with breast cancer.

Surprises and Advances Mark Top Abstracts of 2012

March 7th 2013

An interview with Debu Tripathy, MD, summarizing noteworthy results from the 2012 ASCO Annual Meeting and SABCS, including clinical studies in local, adjuvant, and metastatic breast cancer therapies.

Dr. Richard Finn on the Rationale for Targeting CDK4/6

March 4th 2013

Richard Finn, MD, from Jonsson Comprehensive Cancer Center, discusses the rationale for targeting cyclin-dependent kinases 4 and 6 with the novel agent PD 0332991 in breast cancer.

Dr. Bendell on Hsp90 Inhibition in Advanced Solid Tumors

March 4th 2013

Johanna Bendell, MD, Director of GI Cancer Research Program, Associate Director, Drug Development Program, Sarah Cannon Research Institute, discusses the inhibition of heat shock protein 90 (Hsp90) in advanced solid tumors.

Justin Balko on JAK2 Amplification in TNBC

February 28th 2013

Justin M. Balko, PharmD, PhD, from the Vanderbilt-Ingram Cancer Center, describes a study that discovered JAK2 alterations in patients with treatment-refractory triple-negative breast cancer.

Dr. Vahdat on Frontline Eribulin Plus Trastuzumab in MBC

February 26th 2013

Linda T. Vahdat, MD, from the Weill Cornell Medical College, discusses the combination of eribulin mesylate and trastuzumab as a first-line therapy for HER2-positive metastatic breast cancer.

T-DM1 Approved for HER2-Positive Metastatic Breast Cancer

February 22nd 2013

The FDA has approved ado-trastuzumab emtansine, also known as T-DM1, for HER2-positive metastatic breast cancer.

Alterations in CYP2D6 Enzyme Affect Efficacy of Tamoxifen

February 21st 2013

Genetic or drug-induced alterations of the enzyme CYP2D6 that result in reduced metabolism of tamoxifen are associated with a higher risk of recurrence and death in women with ERâ€“positive breast cancer who receive the drug.

Dr. Twelves Highlights Findings From the 2012 SABCS

February 21st 2013

Christopher Twelves, MD, Professor and Honorary Consultant in Medical Oncology, University of Leeds, highlights key findings from the 2012 San Antonio Breast Cancer Symposium, which took place in December 2012.

Dr. Gradishar on Enriching Targeted Therapy Trials

February 19th 2013

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, describes the need to enrich the patient population in a clinical trial that is investigating a novel targeted therapy.